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Abstract: Positron emission tomography (PET) is used routinely to
follow therapeutic response in patients treated for non-small cell
lung cancer (NSCLC). In responding patients it is generally ex-
pected that the observed decrease in fluorodeoxyglucose uptake
should be similar in all lesions. In other disease entities though,
isolated cases have been documented of asynchronous increases in
activity in metastatic bone lesions (“bone flare”) despite evidence of
therapeutic response or stability in other lesions. Here, we describe
four NSCLC cases in which the results of interim PET scans were
misleading due to osteoblastic flare phenomenon. In all four cases,
patients were treated with bevacizumab in addition to standard
chemotherapy. All four patients developed isolated worsening of
their skeletal metastases on PET/CT (computed tomography) anal-
ysis (increase in fluorodeoxyglucose activity) despite apparent re-
sponse or stable disease elsewhere. Subsequent scans confirmed that
the “worsening” was transient, consistent with a flare response.
Awareness of the phenomena is important for physicians treating
NSCLC patients, particularly with bevacizumab.
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Metastatic bone disease occurs in 30 to 40% of patientswith non-small cell lung cancer (NSCLC).1 In the
initial detection of skeletal involvement, whole body fluoro-
deoxyglucose-positron emission tomography (F18-FDG-
PET) has largely replaced bone scan due to superior speci-
ficity and concurrent tomographic images.1 In various studies
the sensitivity and specificity of PET in detecting untreated
bone metastasis is estimated to be 85 and 99%, respectively.2
There are, however, no guidelines for assessment of response
in metastatic bone lesions. In clinical practice, responding
bone lesions from a NSCLC primary are expected to lose
intensity of FDG uptake in a manner similar to that of visceral
metastases and the primary tumor. However, a paradoxical
flare phenomenon with increase in bone lesion activity de-
spite overall response has been described in several other
solid tumors (breast, prostate, small cell lung cancer).3–5 This
phenomenon represents rapid bone repair around the respond-
ing lesion (increased osteoblastic activity) and may be pre-
dictive of successful systemic therapy.6 It has been reported
that up to 75% of patients with breast cancer with responding
bony metastases show increased activity or new lesions due
to bone repairs, with a subsequent decrease in activity 6
months later.6 Despite the prevalence of this phenomena in
breast cancer, only a few cases of bone flare have been
reported in NSCLC patients on chemotherapy, and all used
bone scan imaging.7 Misinterpretation of bone flare can lead
to premature cessation of successful therapy.
We present four NSCLC patients who developed dis-
crepant increases in FDG activity in bone lesions with oth-
erwise stable or responding disease elsewhere. Skeletal
changes on imaging were indistinguishable from those seen
in progressive disease, and were read as progressive disease
at the time of the initial imaging report. All of these patients
were treated with bevacizumab in addition to standard che-
motherapy.
Case I
A 49-year-old woman with a 3.5 cm left lower lobe
primary adenocarcinoma and diffuse pulmonary and skeletal
metastasis was treated with a platinum doublet and bevaci-
zumab on a clinical trial. Her first follow-up PET/CT (com-
puted tomography) after 2 cycles (6 weeks) showed stable
size and decreased FDG uptake in her lung masses, but
increased uptake in the bone lesions. Concern was raised for
progression in the bones, but given her response elsewhere
she was kept on the same therapy. The next PET/CT after two
additional cycles revealed stability in all lung lesions, but an
even more intense uptake in the previously seen skeletal
lesions. Based on the concern of progression in the bones, the
patient chose to discontinue all therapy. After 4 months off
any conventional cancer therapy, another PET/CT docu-
mented interval progression in the primary mass, multiple
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new pulmonary and bone lesions but was read as “dramatic
interval therapeutic response” in the old skeletal lesions. Thus
at the time of progression, the old bony lesions looked
improved by PET, when they were actually worsening along
with the disease elsewhere. This result was consistent with an
earlier response rather than progression in bony metastases
during initial treatment with chemotherapy and bevacizumab.
Misinterpretation of the results had lead to premature discon-
tinuation of her therapy Figure 1.
Case II
A 71-year-old man with a 4.5 cm right lower lobe
adenocarcinoma, lung metastases and multiple bony metas-
tases including vertebrae was treated on a clinical trial of a
platinum doublet and bevacizumab and a follow up PET/CT
after 2 cycles (6 weeks) showed partial response in all lung
masses and a rib that had received radiation, but increased
tracer uptake in the spinal lesions. After two more cycles of
therapy, the PET/CT demonstrated further decrease in FDG
uptake in the parenchymal lesions, and now significantly
reduced uptake in the spinal metastases as well. This con-
firmed flare as the most likely etiology of the previous noted
increase in activity in that region.
Case III
A 51-year-old man with a 2.7 cm adenocarcinoma in
the left lower lobe, hilar lymphadenopathy, and multiple
hepatic lesions had multifocal metastatic bone disease as
visualized on both a bone scan, and a PET scan. Therapy
with carboplatin, paclitaxel, bevacizumab, and pamidr-
onate led to dramatic improvement in his bone pain.
However, imaging after 3 cycles (9 weeks) revealed a
mixed lytic and blastic lesion involving the right scapula
and glenoid process that had increased in size per plain
film and increased density and size of other lesions on
bone scan (but no new lesions). A PET/CT showed de-
crease in FDG uptake in the lung and liver masses but
increased activity in all previously known bone metasta-
ses. After a 2 week delay in therapy based on concern for
progression, he proceeded with three additional cycles of
chemotherapy and bevacizumab and his next PET showed
decrease in uptake in both skeletal as well as lung paren-
chymal lesions, consistent with earlier bone flare.
Case IV
A 47-year-old woman with a 2 cm left lower lobe
adenocarcinoma, multiple small lung nodules, and numer-
ous bone lesions had resolution of her bone pain after only
one cycle of pemetrexed and bevacizumab on a clinical
trial. A PET scan after 2 cycles of therapy (6 weeks)
demonstrated minimal regression. After four cycles a PET
scan showed stable pulmonary disease, but some increase
in standard uptake value activity of her bone lesions
without corresponding worsening on the CT portion and no
return of her bone pain. On repeat imaging after two more
cycles her tumor size was stable, but FDG uptake of the
bone lesions increased further. Possible progression was
considered, but the patient continued on therapy and after
two additional cycles her subsequent PET scan demon-
FIGURE 1. Patient #1, Fusion Image of changes in positron emission tomography/computed tomography (PET/CT) during
therapy and after therapy cessation focusing on a lung lesion and a lesion in the right humerus. The arms are up on the first
two scans and down on the last one, explaining the positional change of the humerus lesion.
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strated stability in pulmonary disease and lymph nodes and
reduction of standard uptake value activity in all of the
previously seen skeletal lesions.
DISCUSSION
Over a period of several months we observed four
NSCLC patients with evidence of isolated increase in FDG
avidity in metastatic bone lesions despite systemic response
to ongoing therapy with chemotherapy and bevacizumab. In
three of the patients, subsequent imaging demonstrated de-
crease in bone activity with ongoing systemic response,
confirming flare as the etiology. One patient who stopped
chemotherapy and bevacizumab treatment had “improve-
ment” in her bone lesions when all other sites of disease
progressed off treatment, also consistent with an earlier flare
response.
Our experience suggests that bone flare on PET scans
after several cycles of treatment for NSCLC, particularly with
bevacizumab is more common than can be judged from the
literature. It may be that this phenomenon is now being seen
in NSCLC because of the higher response rates seen with
bevacizumab combination regimens. It will be interesting to
evaluate whether in NSCLC there is any correlation between
the development of active bone remodeling, as evidenced by
FDG flare, and improvement in overall survival as has been
reported in breast cancer patients.6
With the development of more effective lung cancer
therapies and widespread use of PET imaging in the follow
up of disease response, the “bone flare” phenomenon previ-
ously described predominantly in breast cancer is now an
issue in NSCLC as well. Practicing oncologists and radiolo-
gists need to be aware of the possibility of this phenomenon
and exercise caution in interpretation of isolated increased
FDG activity in the bone in the setting of otherwise stable or
responding disease. This is particularly true in patients re-
ceiving combination regimens with higher response rates.
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